Teva Pharma Industries Ltd ADR (TEVA)

Teva Pharmaceutical is under fresh antitrust scrutiny in Turkey as the country's competition authority investigates whether the company restricted competition from generic versions of its drugs. The probe focuses on Teva's use of divisional patent procedures and alleged misleading impressions before healthcare authorities regarding competing products. This investigation is similar to a past European Commission case concerning Teva's multiple sclerosis drug, Copaxone, where Teva was fined for abusing its dominant market position.

Teva Pharmaceutical Industries Ltd.'s Chief Accounting Officer, Amir Weiss, exercised stock options for 2,500 Ordinary Shares at $19.16 and subsequently sold a total of 9,445 Ordinary Shares on August 21, 2026. The sales occurred in two blocks: 6,945 shares at a weighted average price of $37.61 and 2,500 shares at $37.63. These transactions were reported in a Form 4 SEC filing, indicating a moderate impact and negative sentiment on the stock titan platform.

Turkish antitrust regulators are investigating Teva Pharmaceutical for allegedly manipulating the patent system and making misleading statements about rival medicines. The probe by Turkey's Competition Board stems from practices that may have been aimed at hindering market entry for competitors. Teva indicated this investigation is similar to a previous European Commission probe, which resulted in a $503 million fine for delaying competition to its Copaxone drug.

Teva Pharmaceutical Industries (TEVA) is gaining attention after the FDA accepted its New Drug Application for ecopipam, a pediatric Tourette syndrome treatment. Despite a significant 1-year return of 103.81%, the company is considered approximately 9.7% undervalued with a fair value of $40.90 against a current price of $36.93, driven by its strategic focus on innovative products and a robust pipeline. However, the article highlights risks such as heavy net debt and dependence on key branded drugs.

Norwich Pharmaceuticals Inc. has been granted a second opportunity by the US Court of Appeals for the DC Circuit to challenge Teva Pharmaceutical Industries Ltd.'s exclusivity for generic versions of Xifaxan. The court ruled that the FDA used an "incorrect causation standard" when determining if Teva had forfeited its 180-day generic sales monopoly. This ruling could allow Norwich to enter the market for generic Xifaxan copies sooner.